Stifel Financial
PGNX

Stifel Financial’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Stifel Financial’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-38,916
Closed -$196K – 3120
2019
Q3 		$196K Buy
38,916
+3,207
+9% +$16K ﹤0.01% 2664
2019
Q2 		$222K Sell
35,709
-4,166
-10% -$20.1K ﹤0.01% 2656
2019
Q1 		$186K Sell
39,875
-529
-1% -$2.39K ﹤0.01% 2608
2018
Q4 		$171K Buy
40,404
+19,361
+92% +$98.6K ﹤0.01% 2490
2018
Q3 		$131K Sell
21,043
-514
-2% -$3.95K ﹤0.01% 2650
2018
Q2 		$172K Sell
21,557
-5,506
-20% -$42K ﹤0.01% 2579
2018
Q1 		$202K Hold
27,063
– – ﹤0.01% 2464
2017
Q4 		$161K Buy
27,063
+1,500
+6% +$9.11K ﹤0.01% 2487
2017
Q3 		$188K Hold
25,563
– – ﹤0.01% 2397
2017
Q2 		$174K Buy
25,563
+24
+0.1% +$177 ﹤0.01% 2383
2017
Q1 		$241K Sell
25,539
-14,711
-37% -$147K ﹤0.01% 2221
2016
Q4 		$348K Buy
40,250
+15,294
+61% +$113K ﹤0.01% 1962
2016
Q3 		$157K Buy
24,956
+1,505
+6% +$9.1K ﹤0.01% 2241
2016
Q2 		$99K Buy
+23,451
New +$113K ﹤0.01% 2385

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stifel Financial's PGNX Position: Q4 2019 in Review

Stifel Financial sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 38,916 shares — an estimated $196K sold.

Stifel Financial first reported a position in PGNX in Q2 2016 and held it in 14 quarters. The position peaked at $348K in Q4 2016. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Stifel Financial reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Stifel Financial sold 38,916 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $196K.
  • Stifel Financial first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 14 quarters.
  • Stifel Financial's Progenics Pharmaceuticals Inc position peaked at $348K in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Stifel Financial's 13F filing for Q4 2019, filed 13 Feb 2020.